The Androgen/androgen Receptor Axis in Prostate Cancer

Overview

Journal Curr Opin Oncol

Specialty Oncology

Date 2012 Feb 14

PMID 22327838

Citations 62

Authors

Eric G Bluemn

Peter S Nelson

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The review highlights recently discovered mechanisms that sustain castration-resistant prostate cancer (CRPC) growth and describes advances in CRPC therapeutics.

Recent Findings: Recent reports have shed new light on the molecular processes underlying CRPC survival during androgen deprivation therapy (ADT). This study summarizes recent findings and comments on their clinical relevance. Included in this review is a discussion on molecular mechanisms that regulate androgen receptor (AR) signaling in normal prostate epithelium and CRPC, biologically significant differences in the androgen-regulated transcriptional programs of androgen-dependent prostate cancer and CRPC, and recent discoveries involving de-novo androgen production and transport. We review the status and results of current clinical trials and finally, discuss the implications of evidence suggesting a declining importance of AR signaling in prostate cancers with PTEN loss.

Summary: Advances in the understanding of AR signaling in CRPC have identified novel drug targets and improved the rational design of targeted therapy, while illuminating a subset of prostate cancers that may progress to become completely independent of the AR signaling program.

Citing Articles

Delineating the role of nuclear receptors in colorectal cancer, a focused review.

Manickasamy M, Jayaprakash S, Girisa S, Kumar A, Lam H, Okina E Discov Oncol. 2024; 15(1):41.

PMID: 38372868 PMC: 10876515. DOI: 10.1007/s12672-023-00808-x.

Arsenic-induced prostate cancer: an enigma.

Mukherjee A, Gopalakrishnan A Med Oncol. 2024; 41(2):50.

PMID: 38184511 DOI: 10.1007/s12032-023-02266-5.

MYB exhibits racially disparate expression, clinicopathologic association, and predictive potential for biochemical recurrence in prostate cancer.

Khan M, Acharya S, Anand S, Sameeta F, Pramanik P, Keel C iScience. 2023; 26(12):108487.

PMID: 38089573 PMC: 10711386. DOI: 10.1016/j.isci.2023.108487.

Orexins and Prostate Cancer: State of the Art and Potential Experimental and Therapeutic Perspectives.

Costagliola A, Lombardi R, Liguori G, Morrione A, Giordano A Cancer Genomics Proteomics. 2023; 20(6suppl):637-645.

PMID: 38035703 PMC: 10687730. DOI: 10.21873/cgp.20412.

Exploring the role of natural bioactive molecules in genitourinary cancers: how far has research progressed?.

Islam F, Nath N, Zehravi M, Khan J, Jashim S, Charde M Nat Prod Bioprospect. 2023; 13(1):39.

PMID: 37843642 PMC: 10579213. DOI: 10.1007/s13659-023-00400-4.

References

Scher H, Beer T, Higano C, Anand A, Taplin M, Efstathiou E . Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010; 375(9724):1437-46. PMC: 2948179. DOI: 10.1016/S0140-6736(10)60172-9. View

Taylor B, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver B . Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22. PMC: 3198787. DOI: 10.1016/j.ccr.2010.05.026. View

Sharma A, Yeow W, Ertel A, Coleman I, Clegg N, Thangavel C . The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest. 2010; 120(12):4478-92. PMC: 2993601. DOI: 10.1172/JCI44239. View

Harris W, Mostaghel E, Nelson P, Montgomery B . Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009; 6(2):76-85. PMC: 2981403. DOI: 10.1038/ncpuro1296. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Whang Y, Armstrong A, Rathmell W, Godley P, Kim W, Pruthi R . A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol. 2011; 31(1):82-6. DOI: 10.1016/j.urolonc.2010.09.018. View

Lin H, Yeh S, Kang H, Chang C . Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A. 2001; 98(13):7200-5. PMC: 34646. DOI: 10.1073/pnas.121173298. View

Tamai I, Nezu J, Uchino H, Sai Y, Oku A, SHIMANE M . Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000; 273(1):251-60. DOI: 10.1006/bbrc.2000.2922. View

Attard G, Reid A, Yap T, Raynaud F, Dowsett M, Settatree S . Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008; 26(28):4563-71. DOI: 10.1200/JCO.2007.15.9749. View

10.

Dehm S, Schmidt L, Heemers H, Vessella R, Tindall D . Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008; 68(13):5469-77. PMC: 2663383. DOI: 10.1158/0008-5472.CAN-08-0594. View

11.

Watson P, Chen Y, Balbas M, Wongvipat J, Socci N, Viale A . Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A. 2010; 107(39):16759-65. PMC: 2947883. DOI: 10.1073/pnas.1012443107. View

12.

Mostaghel E, Marck B, Plymate S, Vessella R, Balk S, Matsumoto A . Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011; 17(18):5913-25. PMC: 3184252. DOI: 10.1158/1078-0432.CCR-11-0728. View

13.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson P, True L . Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One. 2011; 6(11):e27970. PMC: 3219707. DOI: 10.1371/journal.pone.0027970. View

14.

Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T . SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011; 29(18):2565-73. PMC: 3138634. DOI: 10.1200/JCO.2010.31.2405. View

15.

Hagenbuch B, Meier P . The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta. 2003; 1609(1):1-18. DOI: 10.1016/s0005-2736(02)00633-8. View

16.

Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J . Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009; 138(2):245-56. PMC: 2726827. DOI: 10.1016/j.cell.2009.04.056. View

17.

Cai C, He H, Chen S, Coleman I, Wang H, Fang Z . Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell. 2011; 20(4):457-71. PMC: 3225024. DOI: 10.1016/j.ccr.2011.09.001. View

18.

Cai C, Portnoy D, Wang H, Jiang X, Chen S, Balk S . Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res. 2009; 69(12):5202-9. PMC: 4839305. DOI: 10.1158/0008-5472.CAN-09-0026. View

19.

Haelens A, Tanner T, Denayer S, Callewaert L, Claessens F . The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor. Cancer Res. 2007; 67(9):4514-23. DOI: 10.1158/0008-5472.CAN-06-1701. View

20.

Pagliarulo V, Bracarda S, Eisenberger M, Mottet N, Schroder F, Sternberg C . Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol. 2011; 61(1):11-25. PMC: 3483081. DOI: 10.1016/j.eururo.2011.08.026. View